NKTR - Nektar Therapeutics
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
NKTR price evolution
NKTR
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $27.94 | $48.64 | $35.28 | |
| Short term investments | $243.29 | $240.6 | $268.34 | |
| Net receivables | $1.2 | $3.62 | $1.21 | |
| Inventory | $14.46 | $16.24 | $16.1 | |
| Total current assets | $286.48 | $295.19 | $319.84 | $330.7 |
| Long term investments | $19.41 | $36.78 | $25.82 | |
| Property, plant & equipment | $12.43 | $24.43 | $34.74 | $36.86 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $48.15 | $76.18 | $67.33 | |
| Total investments | $262.7 | $277.37 | $294.16 | |
| Total assets | $307.97 | $343.33 | $396.01 | $398.03 |
| Current liabilities | ||||
| Accounts payable | $8.58 | $6.47 | $8.76 | $9.85 |
| Deferred revenue | ||||
| Short long term debt | $21.34 | $19.37 | $19.26 | |
| Total current liabilities | $67.58 | $57.33 | $52.41 | $51.27 |
| Long term debt | $90.76 | $94.71 | $98.52 | |
| Total noncurrent liabilities | $206.32 | $216.9 | $215.78 | |
| Total debt | $112.1 | $114.08 | $117.78 | |
| Total liabilities | $259.08 | $263.65 | $269.31 | $267.05 |
| Shareholders' equity | ||||
| Retained earnings | -$3603.47 | -$3566.41 | -$3514.05 | -$3477.25 |
| Other shareholder equity | $0.35 | -$0.49 | -$0.4 | $0.08 |
| Total shareholder equity | $79.69 | $126.7 | $130.99 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $35.28 | $88.23 | $25.22 | $198.96 |
| Short term investments | $268.34 | $416.75 | $708.74 | $862.94 |
| Net receivables | $1.21 | $5.98 | $22.49 | $38.89 |
| Inventory | $16.1 | $19.2 | $15.8 | $15.29 |
| Total current assets | $330.7 | $545.97 | $795.58 | $1138.01 |
| Long term investments | $25.82 | $64.83 | $136.66 | |
| Property, plant & equipment | $36.86 | $85.89 | $177.53 | $186.14 |
| Goodwill & intangible assets | $76.5 | $76.5 | $76.5 | |
| Total noncurrent assets | $67.33 | $164.63 | $321.61 | $400.76 |
| Total investments | $294.16 | $416.75 | $773.57 | $999.6 |
| Total assets | $398.03 | $710.6 | $1117.19 | $1538.77 |
| Current liabilities | ||||
| Accounts payable | $9.85 | $12.98 | $9.75 | $22.14 |
| Deferred revenue | $2.56 | |||
| Short long term debt | $19.26 | $18.67 | $17.44 | $13.91 |
| Total current liabilities | $51.27 | $68.2 | $85.2 | $115.78 |
| Long term debt | $98.52 | $112.83 | $125.74 | $136.37 |
| Total noncurrent liabilities | $215.78 | $275.76 | $352.48 | $345.69 |
| Total debt | $117.78 | $131.5 | $143.18 | $150.29 |
| Total liabilities | $267.05 | $343.96 | $437.68 | $461.47 |
| Shareholders' equity | ||||
| Retained earnings | -$3477.25 | -$3201.19 | -$2832.99 | -$2309.16 |
| Other shareholder equity | $0.08 | -$6.91 | -$4.16 | -$2.29 |
| Total shareholder equity | $130.99 | $366.64 | $679.51 | $1077.3 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $23.49 | $21.64 | $23.89 | |
| Cost of revenue | $9.74 | $8.53 | $7.28 | |
| Gross Profit | $13.75 | $13.11 | $16.6 | |
| Operating activities | ||||
| Research & development | $29.72 | $27.41 | $29.94 | |
| Selling, general & administrative | $20.51 | $20.15 | $17.32 | |
| Total operating expenses | $63.52 | $48.53 | $50.11 | |
| Operating income | -$49.77 | -$35.43 | -$33.51 | |
| Income from continuing operations | ||||
| EBIT | -$45.91 | -$31.31 | -$35.24 | |
| Income tax expense | $0.05 | -$0.04 | -$0.03 | |
| Interest expense | $6.41 | $5.53 | $6.87 | |
| Net income | ||||
| Net income | -$52.36 | -$36.8 | -$42.08 | |
| Income (for common shares) | -$52.36 | -$36.8 | -$42.08 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $90.12 | $92.06 | $101.91 | $152.91 |
| Cost of revenue | $33.77 | $21.64 | $24.9 | $19.48 |
| Gross Profit | $56.35 | $70.42 | $77.01 | $133.44 |
| Operating activities | ||||
| Research & development | $114.16 | $218.32 | $400.27 | $408.68 |
| Selling, general & administrative | $77.42 | $92.33 | $122.84 | $104.68 |
| Total operating expenses | $320.04 | $446.59 | $523.11 | $558.55 |
| Operating income | -$263.68 | -$376.17 | -$446.1 | -$425.11 |
| Income from continuing operations | ||||
| EBIT | -$250.92 | -$336.07 | -$475.97 | -$437.1 |
| Income tax expense | -$0.2 | $3.21 | $0.56 | $0.49 |
| Interest expense | $25.33 | $28.91 | $47.31 | $6.85 |
| Net income | ||||
| Net income | -$276.06 | -$368.2 | -$523.84 | -$444.44 |
| Income (for common shares) | -$276.06 | -$368.2 | -$523.84 | -$444.44 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$52.36 | -$36.8 | -$42.08 | |
| Operating activities | ||||
| Depreciation | $1.46 | $1.61 | $1.65 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.42 | $6 | $7.25 | |
| Total cash flows from operations | -$37.7 | -$47.89 | -$47.05 | |
| Investing activities | ||||
| Capital expenditures | -$0.19 | -$0.16 | -$0.24 | |
| Investments | $17.17 | $19.41 | $17.62 | |
| Total cash flows from investing | $82.36 | $16.98 | $19.26 | $17.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.02 | -$3 | $0.01 | |
| Net borrowings | $15 | |||
| Total cash flows from financing | $42.03 | $0.02 | $42 | $0.01 |
| Effect of exchange rate | -$0.04 | -$0 | -$0.01 | $0.01 |
| Change in cash and equivalents | -$5.17 | -$20.7 | $13.37 | -$29.64 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$276.06 | -$368.2 | -$523.84 | -$444.44 |
| Operating activities | ||||
| Depreciation | $7.82 | $13.03 | $14.15 | $14.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $33.39 | $57.32 | $94.67 | $94.26 |
| Total cash flows from operations | -$192.61 | -$304.01 | -$412.66 | -$313.29 |
| Investing activities | ||||
| Capital expenditures | $0.38 | $7.52 | -$14.99 | -$7.26 |
| Investments | $139.18 | $358.31 | $217.77 | $503.47 |
| Total cash flows from investing | $139.56 | $365.83 | $202.78 | $496.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.76 | $33.24 | $23.4 |
| Net borrowings | -$250 | |||
| Total cash flows from financing | $0.03 | $1.51 | $36.24 | -$80.35 |
| Effect of exchange rate | $0.06 | -$0.33 | -$0.09 | $0.02 |
| Change in cash and equivalents | -$52.95 | $63.01 | -$173.74 | $102.59 |
News
Fundamentals
| Market cap | $11.24B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 184.46M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 2.04 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.24 |
| Quick ratio | N/A |